Bortezomib
Cyclophosphamide
Second Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Cyclophosphamide cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Second Affiliated Hospital of Soochow University | Phase 3 | BB |
FILGRASTIM Second Affiliated Hospital of Soochow University | Phase 3 | BB |
Cyclophosphamide Second Affiliated Hospital of Soochow University | Phase 3 | BB |
TAMOXIFEN National Cancer Institute (NCI) | Phase 3 | BB |
Ciprofloxacin National Cancer Institute (NCI) | Phase 3 | B |
View all 11 →
Same molecule, other indications
Bortezomib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →